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Histone H3 tail positioning and
acetylation by the c-Myb but not the
v-Myb DNA-binding SANT domain
Xianming Mo, Elisabeth Kowenz-Leutz, Yves Laumonnier, Hong Xu, and Achim Leutz1
Max-Delbrueck-Center for Molecular Medicine, 13092 Berlin, Germany
The c-Myb transcription factor coordinates proliferation and differentiation of hematopoietic precursor cells.
Myb has three consecutive N-terminal SANT-type repeat domains (R1, R2, R3), two of which (R2, R3) form
the DNA-binding domain (DBD). Three amino acid substitutions in R2 alter the way Myb regulates genes and
determine the leukemogenicity of the retrovirally transduced v-Myb oncogene. The molecular mechanism of
how these mutations unleash the leukemogenic potential of Myb is unknown. Here we demonstrate that the
c-Myb–DBD binds to the N-terminal histone tails of H3 and H3.3. C-Myb binding facilitates histone tail
acetylation, which is mandatory during activation of prevalent differentiation genes in conjunction with
CCAAT enhancer-binding proteins (C/EBP). Leukemogenic mutations in v-Myb eliminate the interaction with
H3 and acetylation of H3 tails and abolish activation of endogenous differentiation genes. In primary
v-myb-transformed myeloblasts, pharmacologic enhancement of H3 acetylation restored activation of
differentiation genes and induced cell differentiation. Our data link a novel chromatin function of c-Myb with
lineage-specific expression of differentiation genes and relate the loss of this function with the leukemic
conversion of Myb.
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Classical retroviral oncogenes induce transformation
and tumorigenic conversion of particular cell types at
distinct differentiation stages and in distinct tissues.
This suggests that retroviral oncoproteins interfere with
epigenetic processes that direct cell maturation and mul-
tiplication.
The retroviral oncoprotein v-myb of avian myeloblas-
tosis virus (AMV) is an example of an abducted and mu-
tated version of a cellular transcription factor that plays
a decisive role in blood cell development, proliferation,
and differentiation (Hall et al. 1941; Mucenski et al.
1991). The cellular predecessor of v-myb, the proto-on-
cogene c-myb, encodes a metabolically labile gene regu-
latory protein that is essential for adult hematopoiesis.
Myb has been repeatedly captured by avian leukemia
viruses. Its genomic locus is also a frequent target of
retroviral integration in mice. In addition, the c-MYB
gene is overexpressed in a variety of human leukemias,
and its down-regulation is a prerequisite for proliferation
arrest (Wolff 1996). Transgenic mice that overexpress c-
Myb protein, however, do not develop tumors (Furuta et
al. 1993), suggesting that the proto-oncoprotein c-Myb
requires further activation to unleash its tumorigenic po-
tential (Graf 1992; Lipsick 1996). In addition to prolifera-
tion control, several lines of evidence also suggest that
c-Myb is involved in cell differentiation (Ness et al.
1993; Kasper et al. 2002; Emambokus et al. 2003), raising
the possibility that the cellular role of the Myb protein is
to coordinate cell multiplication and cell specification.
The AMV strain transduces an acutely transforming
N- and C-terminally truncated viral Myb (v-Myb) onco-
protein that also harbors 11 amino acid substitutions.
AMV induces myeloid leukemia in chicken and trans-
forms myeloid precursors (myeloblasts) in vitro (Graf
and Stehelin 1982; Ness 1996; Lipsick and Wang 1999).
Whereas truncation of Myb activates the protein, several
of the amino acid substitutions sustain the transforma-
tion strength of v-myb (Dini et al. 1995). Three muta-
tions in the DNA-binding domain (DBD) of v-Myb, how-
ever, determine both the cell lineage specificity and the
leukemogenic potential in the animal (Introna et al.
1990). Interestingly, these amino acid substitutions do
not affect recognition of cis-regulatory Myb-binding sites
on DNA (Brendeford et al. 1997). Structural analysis
showed that these three critical amino acid substitutions
replace solvent-exposed hydrophobic amino acid side-
chains (I91, L106, and V117 are replaced by N, H, and D,
respectively) that are located on a side of Myb that faces
away from the DNA (Tahirov et al. 2002). Accordingly,
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these data may indicate that v-Myb is devoid of protein
interactions that normally prevent a leukemogenic ac-
tivity of c-Myb.
The C-terminal leucine zipper of CCAAT enhancer-
binding protein  (C/EBP) interacts with the surface of
R2 in c-Myb, and the AMV-specific amino acid substi-
tutions in R2 abrogate accommodation of C/EBP (Bren-
deford et al. 1997; Tahirov et al. 2002). Concomitantly,
C/EBP and v-Myb fail to cooperate in the activation of
the prototypal differentiation genes mim-1 and lysozyme
(Introna et al. 1990; Kowenz-Leutz et al. 1997). Although
the structural data provided a compelling explanation for
failure of v-myb to participate in cell maturation and to
block differentiation, individual back mutations, do-
main swap mutants of Myb (this study; A. Leutz and E.
Kowenz-Leutz, unpubl.), and leucine zipper exchange
mutants in C/EBP (swap of C/EBP leucine zipper to that
of the cAMP response-binding protein, CREB; data not
shown) indicated that the physical interaction between
Myb and C/EBP and activation of endogenous genes
could be separated. Accordingly, the R2 mutations in
v-myb appear to extinguish another important function
of Myb.
Each of the three Myb repeats—including R2 and R3,
which together establish a compound DBD—carry the
architectural signature of the chromatin-interacting
SANT domain, previously identified in several chroma-
tin regulatory proteins (e.g., the Swi3, Ada2, TFIIIB,
NcoR, and ISWI proteins) (Aasland et al. 1996). However,
a direct connection between Myb domains that bind to
DNA and chromatin remodeling has not yet been
shown. SANT domains appear to be devoid of enzymatic
activity but are functionally involved in histone acety-
lation, deacetylation, and ATP-dependent remodeling
(Boyer et al. 2002; Sterner et al. 2002). Several reports on
SANT domain functions indicate that this domain
serves as a protein interaction domain that binds to his-
tone modifying enzymes while it simultaneously facili-
tates substrate recognition and enhances enzyme activ-
ity (see Discussion).
Here we show that the wild-type Myb–DBD, but not
its leukemogenic v-Myb cousin, interacts with the N-
terminal tail of histone H3 and positions it for acetyla-
tion. Both histone tail binding and acetylation are pre-
requisites for the activation of differentiation genes.
These data thus demonstrate for the first time that Myb
displays a function in chromatin organization by direct-
ing histone modifications through its SANT–DBD, and
that these functions are lost in its leukemogenic coun-
terpart.
Results
The Myb SANT–DBD binds to the N-terminal tail
of histone H3
Protein interaction screening using the SANT-Myb do-
main of c-myb or v-myb to disclose binding partners has
been largely deferred by the toxicity of the Myb–DBD in
yeast. We argued that this could be due to the fact that
the domain binds to yeast DNA and interferes with gene
expression. We sought to overcome this limitation by
introducing a mutation in the Myb–DBD (MybK128M)
that is deficient for binding to cis-regulatory Myb sites
but that retains the overall SANT domain structure and
that could therefore be used as a bait for screening (Oda
et al. 1998).
The mutant Myb–DBD-bait (MybK128M) was used in
a yeast two-hybrid screen (Ansieau and Leutz 2002) of an
adult human bone marrow cDNA library. A full-length
clone of the human histone H3 variant H3.3 was iso-
lated. The specificity of the interaction between c-Myb
and histones was examined by subjecting purified hu-
man histones to a GST–c-Myb DBD construct. As shown
in Figure 1A, only histone H3 interacts with GST–c-
Myb–DBD, confirming the screening result.
Nucleosomal histone proteins consist of regulatory N-
terminal flexible tail and nucleosomal C-terminal core
domains. The H3.3 tail domain (amino acids 1–42) and
the core domain (amino acids 42–136) were expressed
separately as GST constructs and examined for interac-
tion with the Myb–DBD. As shown in Figure 1B, only
the N terminus, but not the core, of H3.3 interacts
strongly with the Myb–DBD. Since H3 and H3.3 have
highly conserved N-terminal domains (Fretzin et al.
1991; Akhmanova et al. 1995), we compared the inter-
Figure 1. C-Myb–DBD Interacts with the histone H3 tail. (A)
Matrix-bound GST–c-Myb–DBD was subjected to purified, re-
combinant human histones as indicated on the top. Beads were
extensively washed, and bound protein was subjected to SDS-
PAGE and revealed by silver staining. (B) GST–histone H3.3
fragments (amino acids 1–42 and 42–136), as indicated, or GST
control was incubated with in vitro 35S-methionine-labeled c-
Myb–DBD. Specifically bound proteins were subjected to SDS-
PAGE and revealed by fluorography. (C) Affinity binding as in B
using GST–histone tail (human) constructs of H2A, (amino ac-
ids 1–35), H2B (amino acids 1–35), H3 (amino acids 1–46), H4
(amino acids 1–34), or H3.3 (amino acids 1–42). (D) Comparison
of c-Myb binding to various GST–histone H3 tail constructs.
Bottom panels (GST protein) in B–D show Coomassie stain of
GST constructs used in the binding experiments as shown
above. Input represents 15% of the material used for pull-down
assays.
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action between c-Myb and both H3 and H3.3 N-terminal
histone tails to the N-terminal tails of other histones. As
shown in Figure 1C, both H3 and H3.3 N termini bind to
c-Myb–DBD, whereas the N termini of H2A, H2B, and
H4 failed to do so. Further mapping of the H3 N-terminal
tail, as shown in Figure 1D, suggests that the major bind-
ing site for c-Myb–DBD resides between amino acid resi-
dues 27 and 42 of H3.
Interaction between the N terminus of H3 and c-Myb
or v-Myb
The retrovirally transduced v-Myb leukemia protein of
AMV carries four amino acid substitutions in its v-Myb–
DBD (three in R2—I91, L106, V117—and one, I181, in
R3, are replaced by amino acids N, H, D, and V, respec-
tively) (positions are indicated by dots in Fig. 2A).
Whereas the R3 mutation represents a conservative
amino acid exchange that has not been found to affect
the Myb biology, single R2 back mutations of v-Myb to
the wild-type configuration (N91I, H106L, or D117V)
dramatically alter the phenotype and differentiation
stage, restore the ability to activate differentiation genes
in concert with C/EBP, and diminish the leukemogenic
potential (Introna et al. 1990). Thus, the v-myb R2 mu-
tations (I91N, L106H, and V117D) are essential for the
myeloid differentiation block, maintenance of self-re-
newal during transformation and tumorigenicity.
Binding assays with v-Myb and c-Myb were performed
to determine whether wild-type and leukemogenic Myb
proteins interact differentially with the H3 tail. As
shown in Figure 2B, truncated c-Myb binds to the H3
tail, whereas v-Myb did not. Individual back mutations
in v-Myb to c-Myb–DBD that decrease its leukemogenic-
ity and alter the transformed phenotype restored the in-
teraction with the H3 tail (Fig. 2B).
Amino acid substitutions, such as those that occur in
v-Myb, were introduced into R2 of c-Myb to further dis-
criminate between effects of the DBD and mutations
elsewhere in the oncoprotein. As shown in Figure 2C,
the three AMV-specific amino acid substitutions of R2
(I91N, L106H, V117D) that are critical for its leukemo-
genic potential also abrogated binding to H3. Individual
amino acid substitutions (data not shown) or double sub-
stitutions (Fig. 2C) in the c-Myb R2-SANT domain were
not sufficient to abrogate interactions with the H3 tail.
These results show that the c-Myb–DBD interacts with
the H3 tail and that the triad of v-Myb–DBD amino acid
substitutions, previously shown to determine both the
leukemogenicity and the transformed phenotype, is si-
multaneously required to abolish the interaction with
the H3 tail.
Although c-Myb and v-Myb display similar DNA se-
quence binding specificities, it has been suggested that
the DNA–protein complexes exhibit different stabilities
(Brendeford et al. 1997). To exclude the possibility that
decreased DNA binding accounts for a loss of H3 inter-
action on endogenous Myb-target genes, we first com-
pared binding of v-Myb and c-Myb to target genes by
chromatin immunopreciptation assay (ChIP, schemati-
cally shown in Fig. 3A). As shown in Figure 3B, wild-type
and all mutated Myb proteins interact with their natural,
chromatin-embedded target genes in cells, although
some quantitative differences of promoter-bound Myb
variants were observed (Fig. 3B,C) that might be due to
differences in local promoter architectures or antibody
accessibility during ChIP. Nevertheless, these results
show that the mutations in the v-Myb protein do not
prevent its association with target promoters. Accord-
ingly, the interaction with H3 tails is not required for
Myb to find its binding sites in responsive genes. Of par-
ticular attention is the v-Myb N91I back mutation (Fig.
3C, v-mybIHD) that was reported to display somewhat
reduced DNA-complex stability similar to v-Myb (Bren-
deford et al. 1997). Similar ChIP quantities of both v-
Myb and v-Myb N91I were recovered, but only the v-
Myb N91I mutant regained H3 tail binding (Fig. 2) con-
comitantly with the activation of differentiation genes
and the loss of leukemic differentiation block (Introna et
al. 1990). The results shown in Figure 3 therefore dem-
onstrate that the leukemogenic potential and the myelo-
monocytic differentiation block of v-Myb converge
Figure 2. Configuration of the Myb–DBD and H3 tail binding.
(A) Overview of Myb constructs and summary of H3 binding
data as shown in B and C. (B) In vitro-translated, 35S-methio-
nine-labeled c-Myb (N- and C-terminally truncated, amino ac-
ids 80–497) or v-Myb was incubated with matrix-bound GST–
histone tails or GST as a control. (Upper panels) Specifically
bound proteins were revealed by SDS-PAGE and fluorography.
GST panel shows unspecific binding to GST control, and input
panel represents 15% of the labeled material used for pull-down
assays. Bottom panel shows protein stains of GST–H3 and GST
as indicated. (C) Pull-down of various 35S-methionine-labeled
Myb–DBD proteins by GST–H3. Matrix-bound GST fusion pro-
teins were incubated with in vitro-translated, labeled Myb–
DBD mutants. Input represents 15% of the labeled material
used for pull-down assays.
SANT domain function of Myb
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through the three amino acid substitutions in the abro-
gation of H3 interaction.
H3–Myb interaction and histone acetylation
The c-Myb and v-Myb proteins interact through their
transactivation domain with the KIX domain of the his-
tone acetyl transferase (HAT) p300 (Mink et al. 1997;
Kasper et al. 2002). The interaction between Myb and
p300 is essential for target gene activation and Myb-de-
pendent megakaryocyte differentiation (Kasper et al.
2002). Although the p300–Myb interaction does not ap-
pear to involve the Myb–DBD, we assessed whether v-
Myb–DBD mutations might nonetheless affect the inter-
action with p300 on cellular genes. As shown in Figure
4A, ChIP analysis revealed that enhanced association of
p300 with Myb target genes depends on the presence of
Myb but is not affected by v-Myb–DBD mutations. In
addition, immunoprecipitation (Fig. 4B) showed that
Myb associates with p300 irrespective of the amino acid
substitutions in the DBD and thus independently of the
interaction between the Myb–DBD and the histone H3
tail (Fig. 4B).
P300 and/or potentially p300-associated acetyl trans-
ferases may catalyze the acetylation of K18 and K23 of
the H3 N terminus during gene activation in vivo (Dau-
jat et al. 2002). We therefore determined whether various
Myb derivatives would catalyze the acetylation of H3
tails at endogenous Myb target genes in the absence and
presence of cotransfected p300. As shown in Figure 5A,
acetylation of H3 K18 and K23 at both Myb target genes,
mim-1 and lysozyme, was enhanced by c-Myb or Myb
derivatives that contain one of the three critical R2
amino acids in wild-type configuration. Moreover, co-
transfected p300 enhanced H3 acetylation under these
conditions. No such H3 acetylation-dependent ChIP
fragments were found in the vector controls, or with v-
Myb or with c-myb that harbor the three critical v-Myb
amino acid substitutions in R2. Furthermore, individual
back mutations in v-Myb toward the c-Myb–DBD con-
figuration, which abate leukemogenicity and change
phenotype, also restored the ability to promote acetyla-
tion of H3 tails. In addition, methylation of H3 R17 was
detectable in p300-transfected cells in combination with
c-Myb but not with v-Myb, whereas no changes were
seen on H4 K5 or K8 acetylation (data not shown). These
data suggest that several histone modifications might
occur when Myb interacts with p300 and H3 tails, po-
tentially by p300-associated CARM1 (Xu et al. 2001;
Daujat et al. 2002). Next, we examined the H3 acetyla-
tion stage in primary chick bone marrow cells infected
Figure 4. c-Myb and v-Myb proteins recruit p300 to chroma-
tin-embedded promoters independently of H3 tail binding. (A)
C-Myb and v-Myb proteins or mutants of c-Myb or v-Myb were
transfected together with HA-tagged p300 into QT6 fibroblasts.
Chromatin was immunoprecipitated with anti-HA antibody.
Coprecipitated DNA was analyzed by PCR amplification. A
negative image of an ethidium bromide-stained gel is shown.
(Lower panel) Input lanes represent 0.1% of material used for IP.
(B) Myb and p300 expression and IP controls. v-Myb proteins
were expressed together with p300 in QT6 fibroblasts. (Left) IP
with HA or preimmune serum samples were separated by SDS-
PAGE, blotted, and revealed by anti-Myb immunostaining. Cell
lysate controls of SDS-PAGE separated and blotted proteins
show expression of transfected Myb and p300 proteins.
Figure 3. Target gene binding of Myb is independent of H3 tail
binding. (A) Schematic representations of mim-1 and lysozyme
genes indicating the location of amplification products (gray
bars), TATA boxes, transcription start sites (+1), and transcrip-
tion stop sites. (B) Truncated c-Myb proteins (amino acids 80–
497), amino acid substitution mutants of c-Myb, or vector con-
trols were transfected into QT6 fibroblasts. Cell lysates were
analyzed by ChIP with anti-Myb antibody, and coimmunopre-
cipitated DNA was PCR amplified, separated by electrophore-
sis, and shown as a negative image of an ethidium bromide-
stained gel. Input lanes (lower panel) represent 0.1% of material
used for IP. Myb constructs as shown in Figure 2A. (C) Same as
in B using v-Myb and mutants of v-Myb.
Mo et al.
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with various retroviral Myb constructs (Fig. 5B). The re-
sults show that also in primary myeloblasts, under
physiological conditions, acetylation of H3 at the endog-
enous mim-1 promoter reflects the configuration of the
R2 SANT domain, confirming the data presented in Fig-
ure 5A. Thus, although all Myb derivatives that contain
the transactivation domain can recruit p300 to their tar-
get genes, only those Myb proteins that also interact
with the H3 tail promote H3 acetylation in the vicinity.
These results therefore indicate that (1) the c-Myb-R2
SANT domain is involved in H3 positioning in nucleo-
somes for subsequent acetylation, and (2) v-Myb is de-
fective for this function and withdraws from assisting in
the expression of genes required for cell differentiation.
Gene activation and Myb-mediated H3 acetylation
C/EBPs collaborate with c-Myb but not with v-Myb to
activate myeloid genes (Ness et al. 1993; Kowenz-Leutz
et al. 1997). The N terminus of C/EBP supplies the
chromatin remodeling complex SWI/SNF that is essen-
tial for cell differentiation and for the activation of a set
of granulocytic genes (Kowenz-Leutz and Leutz 1999;
Pedersen et al. 2001). The DBD of c-Myb, but not the
DBD of v-Myb, can interact with the bZip region of
C/EBP when both transcription factors are bound to
their cis-regulatory sites at a distance and loop out in-
tervening DNA (Ness et al. 1993; Tahirov et al. 2002).
We therefore wondered about the importance of the in-
dividual contributions of H3 tail acetylation by Myb, on
one hand, and SWI/SNF recruitment by C/EBP, on the
other hand. To address this question, several chimeric
Myb mutants were constructed that combine viral and
cellular Myb with the N terminus of C/EBP (Fig. 6A).
We have previously shown that fusing the N-terminal
SWI/SNF recruiting domain of C/EBP to Myb yields a
chimeric transcription factor that forcefully recruits
SWI/SNF and thus supersedes further C/EBP require-
ment to activate endogenous Myb target genes (Kowenz-
Leutz and Leutz 1999). As shown by immunoprecipita-
tion in Figure 6B, chimeras between the N terminus of
C/EBP and c-Myb or v-Myb proteins may recruit the
SWI/SNF complex as indicated through binding of
brahma (hBrm), a core factor of the SWI/SNF complex
(Fig. 6B, upper panel). Expression controls (Fig. 6B, lower
panel) further showed similar expression of the con-
structs. ChIP assays (Fig. 6C) of the mim-1 promoter fur-
ther revealed that both N-c-myb and N-v-myb chime-
ras may recruit brahma and p300 to the mim-1 promoter,
suggesting that chromatin remodeling plus histone
modification machineries are available at relevant genes.
However, acetylation of H3 occurs only with Myb con-
structs that harbor wild-type Myb R2–SANT domains.
Gene expression examined by Northern blotting (Fig.
6D) further revealed that activation of the endogenous
mim-1 target gene, which essentially requires SWI/SNF,
nevertheless remains entirely dependent on the ability of
R2 to interact with H3 tails. These data suggest that both
chromatin remodeling and histone acetylation may oc-
cur independently of each other but are required for the
activation of endogenous genes. The data also suggest
that the oncogenic R2 domain of v-myb represents a loss
of function that defeats interaction with and acetylation
of H3 tails to block activation of differentiation genes.
These results imply that Myb H3 tail interaction
and acetylation is a bottleneck during the activation
of differentiation genes by Myb transcription factors.
The acetylation state of histones, however, is balanced
by histone acetylases and histone deacetylases (HDACs).
We therefore wondered whether the HDAC inhibitor
Trichostatin A (TSA), which enhances H3 acetylation,
would override repression of differentiation genes in
v-myb-transformed hematopoietic cells. To test this
possibility, chick bone marrow cells were infected with
the classical leukemogenic AMV, and transformed my-
eloblasts were grown without and with TSA to mon-
itor H3 acetylation and gene expression in primary leu-
kemic cells. As shown in Figure 7A, both mim-1 and
lysozyme genes were barely expressed in AMV-trans-
Figure 5. Acetylation of H3 K18 and K23 at Myb target genes
depend on H3 tail binding and p300 recruitment by Myb. (A)
Vector control or c-Myb proteins and mutants thereof were
transfected into QT6 cells without (left) or together with (right)
p300, as indicated on the top. Chromatin was immunoprecipi-
tated with antibodies directed toward acetylated H3 K18 or K23
as shown on the left. Coprecipitated DNA was analyzed by PCR
amplification. A negative image of an ethidium bromide-stained
gel is shown. Input lanes represent 0.1% of material used for IP.
(B) Bone marrow cells were isolated from a 1-d-old chicken and
infected with recombinant viruses encoding truncated c-myb or
myb–DBD mutants as shown on the right (retroviral constructs
indicate lanes of ChIP analysis) and in Introna et al. (1990).
Transformed myeloblasts were expanded under appropriate
conditions, and ChIP analysis was performed from as indicated
on the right.
SANT domain function of Myb
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formed myeloblasts. Treatment with TSA, however,
strongly enhanced the acetylation of H3 K18 and K23
and concomitantly strongly enhanced Myb-target gene
expression. Controls showed equal loading of RNA blots,
and v-Myb and C/EBP controls showed only minor ef-
fects of TSA on protein expression. Moreover, TSA treat-
ment overcame the v-myb differentiation block and
induced morphologic differentiation of self-renewing
myeloblasts growing in suspension into adherent mac-
rophages (Fig. 7B). Taken together, these data show that
the differentiation block of the classical v-myb oncogene
is linked to a defective epigenetic function of the onco-
protein.
Discussion
Here we describe a novel function of c-Myb: The DBD of
c-Myb is able to bind to the N-terminal tail of histone H3
and to make it accessible for acetylation. Binding of the
Myb–DBD to histones is specific for H3 and H3.3 tails
and is a prerequisite for the activation of myeloid genes
characteristically expressed in differentiating cells. The
leukemogenic v-Myb version transduced by the classical
AMV carries three amino acid substitutions in its DBD
that disrupt H3 interaction, H3 tail acetylation, and, sub-
sequently, the activation of chromatin embedded genes
involved in cell differentiation. Our results show for the
first time that the c-Myb–DBD carries a function that is
characteristic for SANT domain proteins involved in his-
tone acetylation and that v-Myb is deficient in cata-
Figure 6. The Myb–DBD determines H3 tail acetylation and
gene activation in chimeric C/EBP–Myb domain swap pro-
teins. (A) Schematic representation of the constructs. C/EBP
has an N-terminal SWI/SNF recruiting and transactivation do-
main (N, amino acids 1–116), a central regulatory domain (RD)
and a C-terminal b-Zip domain. The Myb–DBD is indicated as
a black box. R2 and R3 Myb repeats are shown as triangles
(white and gray triangles represent c-Myb and v-Myb DBD, re-
spectively), and v-Myb mutations are indicated as black dots.
The C-terminal transactivating fragment of c-Myb or v-Myb
(TAD) are depicted as white and gray boxes. Chimeric con-
structs consist of the C/EBP N terminus (N) fused in frame to
Myb. Chimeric Myb proteins consisted of c-Myb (N-C-C) or
v-Myb (N-V-V), or domain swaps (N-C-V; N-V-C) as indi-
cated. (B, upper panel) Fusion proteins as indicated were trans-
lated in vitro in the presence of 35S-methionine and mixed with
or without (+/−) in vitro-translated hemagglutinine HA-tagged
hBrm (without radioactive label), as indicated. Complexes were
immunoprecipitated with a HA-specific antibody (HA-IP, in-
dicated on the top) and revealed by SDS-PAGE and fluorogra-
phy. Input lanes represent 10% of material used for IP. (Lower
panel) Cell lysate controls of SDS-PAGE separated and blotted
proteins to show expression of chimeric proteins. (C) Expression
vectors encoding chimeric proteins as indicated were trans-
fected together with the coactivators or combination thereof as
indicated on the top. ChIP was performed using antibodies to
HA, p300, or acetylated H3 as indicated on the left. Coprecipi-
tated DNA encompassing the mim-1 promoter was analyzed by
PCR amplification. A negative image of an ethidium bromide-
stained gel is shown. Input lanes represent 0.1% of material
used for IP. (D) Expression vectors encoding chimeric proteins
as indicated in A or controls (c-myb + C/EBP, vector, c-myb,
C/EBP, v-myb) were transfected into QT6 fibroblasts. RNA
was harvested after 24 h, and RNA blots were probed with
mim-1 and subsequently with GAPDH as internal control.
Figure 7. TSA overrides the v-myb differentiation block and
activates histone acetylation and myeloid differentiation genes.
(A) AMV-transformed myeloblasts were treated without or with
TSA (+/− TSA) as indicated. Polyadenylated RNA was analyzed
by Northern blotting, and cellular protein was analyzed by SDS-
PAGE and Western blotting. (B) Micrographs of AMV-trans-
formed myeloblasts. AMV-myeloblasts grow as suspension cells
(−TSA) and acquire an adherent macrophage phenotype when
treated with TSA (+TSA) for 48 h.
Mo et al.
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lyzing this covalent chromatin modification, linking de-
fective chromatin remodeling by v-Myb to its tumori-
genic potential.
Differential H3 tail acetylation by c-Myb and v-Myb
The results presented here show that the c-Myb–DBD
interacts specifically with histone H3 and/or H3.3 tails.
The physical interaction between H3 tail and c-Myb–
DBD is required for acetylation of K18 and K23 and is a
prerequisite for gene transcription. Our results show that
acetylation of both sites occurs in a p300-dependent
fashion. Although it has been shown that K18 and K23
are targets of acetylation by p300, we can not distinguish
whether p300 itself or another associated his-
tone acetyltransferase (HAT) modifies the N terminus of
H3 in a Myb-dependent fashion. Regardless of the mo-
lecular details, it is conceivable that the interaction be-
tween Myb and the H3 tail positions the flexible H3 N
terminus for its subsequent modification by histone
modifying enzymes, including acetylation of K18 and
K23.
Mutations in the DBD that render v-Myb leukemo-
genic abolish the interaction with H3 tails. As a conse-
quence, H3 tails at mim-1 and lysozyme loci are not
acetylated at K18 and K23 in the presence of v-Myb and
both genes remain silent. Our data thus provide an ex-
planation for how c-Myb participates in the modification
of chromatin during activation of differentiation genes
and argues for a dominant-negative role of its leukemic
counterpart v-Myb. It is interesting to note that among
the mutations accrued in v-Myb, only the three amino
acid substitutions affecting R2 of the Myb DBD are re-
quired simultaneously to maintain its high leukemo-
genic potential. Any back mutation to the wild-type
configuration in R2 diminishes the leukemogenicity,
prolongs the latency, alters the phenotype of trans-
formed cells, and restores the interaction with and the
acetylation of the H3 tail. It has been shown that
the three amino acid substitutions in R2 remove a hy-
drophobic patch on the surface of R2, and alter the pack-
aging mode of the hydrophobic R2 core (Tahirov et al.
2002). It has also been suggested that the R2 surface
might participate in the interaction between c-Myb
and other coregulatory factors such as p100 and Cyp40
(Leverson and Ness 1998; Leverson et al. 1998), D-type
cyclins (Ganter et al. 1998), HSF3 (Kanei-Ishii et al.
1997), or C/EBP (Tahirov et al. 2002). It will therefore
be interesting to uncover the structural basis of the
histone c-Myb interaction to further examine whether
c-Myb interacts with other proteins and H3 simulta-
neously.
Differential interaction between C/EBPs and c-Myb
or v-Myb
The c-Myb and v-Myb DBDs were previously shown to
differentially interact with C/EBPs, a family of trans-
activators involved in hematopoietic lineage decision
and in proliferation control. C/EBPs are required for
the synergistic activation of myeloid genes and for my-
eloid cell maturation (Ness et al. 1993; Muller et al.
1995). Removal of the hydrophobic patch on R2 by
the leukemogenic v-Myb mutations disables the in-
teraction with the C-terminal bZip domain of C/EBPs.
It was therefore speculated that failure of the v-Myb–
DBD to interact with C/EBP might reflect the block
in differentiation and the leukemogenic potential of
v-Myb (Tahirov et al. 2002), a conclusion that is difficult
to reconcile with biological results obtained with a
C/EBP-binding-deficient v-Myb mutant (Introna et al.
1990). Results presented here suggest, however, that
defective histone acetylation is a domineering effect of
the v-Myb oncoprotein that, together with a defective
C/EBP interaction, inhibits activation of differentiation
genes.
This conclusion is derived from results obtained with
chimeric proteins that fuse the transactivation domain
of C/EBP with either c-Myb or v-Myb. We have shown
previously that a chimeric c-Myb construct with the
C/EBP N terminus fused to Myb takes over functions of
the otherwise bipartite Myb–C/EBP switch: The chi-
meric protein recruits the SWI/SNF complex and thus no
longer requires solitary C/EBP during mim-1 and lyso-
zyme activation (Kowenz-Leutz and Leutz 1999). The
transcriptional cooperation between Myb and C/EBP
therefore occurs through functional domains on different
transcription factors that can be combined into a single
transcription factor. In fact, the fusion protein that con-
tains c-Myb and the C/EBP N terminus becomes hyper-
active for mim-1 transcription, compared with the regu-
lar C/EBP–Myb interaction. This suggests that coopera-
tive events that occur between functional domains
located on different transcription factors may become
more efficient once the two proteins are in close prox-
imity. It was therefore surprising to observe that a simi-
lar chimeric transcription factor that carries only the R2
SANT domain mutations of v-Myb entirely failed to ac-
tivate target genes. This finding suggested that although
all required components, such as the SWI/SNF and his-
tone acetylation complexes, are recruited to target loci,
acetylation of H3 tails remains essential and can not be
bypassed by forced SWI/SNF recruitment.
The data also suggest that remodeling and acetylation
at target loci may occur independently of each other and
are simultaneously required during gene activation in
our experimental setting. What remains to be deter-
mined is whether in normal hematopoiesis both events
are temporally separated. Published data from others
suggest that loci of myeloid genes are somehow primed
early in hematopoietic precursor cells, before the onset
of expression of differentiation genes. Yet, TSA treat-
ment of precursors that do not express C/EBP leads to
profound alterations at the −3.9-kb lysozyme enhancer
without inducing lysozyme expression, whereas TSA
treatment in cells that do express C/EBP also induced
lysozyme gene expression (Kontaraki et al. 2000; Lefevre
et al. 2001). However, how this relates exactly to acety-
lation of histones or remodeling of nucleosomes at rel-
SANT domain function of Myb
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evant sites has still to be addressed. Nevertheless, the
data presented here and by others suggest that SWI/SNF-
mediated remodeling at target sites becomes imperative
for gene transcription in concert with H3 modifications
and vice versa.
Gain and loss of functions of v-Myb
The inability of v-Myb to bind to H3 tail and to C/EBP
lends support to the idea that the v-Myb–DBD mutations
convert the protein into a dominant-negative transcrip-
tion factor (Lipsick and Wang 1999). However, at least
one target gene of Myb, termed GBX2, is activated con-
stitutively by v-Myb but not by c-Myb. In contrast to
myeloid differentiation genes that are coregulated by
C/EBPs, activation of GBX2 depends on the three R2
mutations in v-Myb (Kowenz-Leutz et al. 1997). Accord-
ingly, failure to bind to H3 and to acetylate H3 by v-Myb
could still permit the activation of some genes. We have
shown previously that GBX2 becomes activated by c-
Myb once a receptor tyrosine kinase pathway (RTK) is
concomitantly activated (Kowenz-Leutz et al. 1997).
This raises the interesting possibility that during RTK
signaling, c-Myb functions in H3 positioning, acetyla-
tion, or both might be transiently altered, reflecting a
constitutive function of v-Myb. One possibility is that
such Myb-target genes do not depend on Myb binding to
cis-regulatory sites on DNA but on interactions between
Myb and other transcription factors that transmit Myb
functions unrelated to H3 tail acetylation (Schubert et al.
2004). Yet another possibility is that critical activities of
Myb in proliferation might still require distinct Myb
functions, such as p300 binding, but that these functions
are nontranscriptional; such as, for example, during
DNA replication (Beall et al. 2002). Although it is diffi-
cult to distinguish between these possibilities, our re-
sults suggest that the function of c-Myb during differen-
tiation depends on H3 tail acetylation and that this func-
tions becomes abrogated by R2 mutations in the
oncogene. This conclusion is also supported by the result
that inhibition of deacetylation, which leads to strongly
enhanced, genome-wide H3 acetylation, could induce
transcription of differentiation genes and myeloid differ-
entiation of primary v-Myb-transformed myeloblasts,
similar to what has been seen by others using an AMV-
transformed cell line (Nemajerova et al. 2003).
Leukemogenic v-Myb has a defective SANT domain
The SANT domain was identified based on its similarity
with Myb-repeats found in many proteins involved in
chromatin regulation (Aasland et al. 1996). SANT do-
mains are not only binding modules but are also in-
volved in enzymatic reactions of several chromatin re-
modeling enzyme complexes. Examples are the yeast
HAT complexes SAGA and ADA that possess a number
of transcriptionally relevant subunits, including a trim-
eric module consisting of the HAT Gcn5, Ada3, and the
SANT domain protein Ada2p (Grant et al. 1997). Muta-
tional analysis revealed that the Ada2p SANT domain is
required for Gcn5 interaction, for full HAT activity me-
diation in the SAGA complex, and for recognition of
nucleosomal substrates (Boyer et al. 2002; Sterner et al.
2002). SANT domain functions were therefore suggested
to include histone tail presentation, alignment of sub-
strate and catalytic sites for chromatin acetylating en-
zymes, and modulation of enzyme functions (Boyer et al.
2002). SANT domain proteins are, however, also found
in other chromatin remodeling complexes. The N-CoR
corepressor of nuclear receptors is a SANT domain pro-
tein that interacts with and stimulates HDAC3 (Zhang
et al. 2002). Another SANT domain protein, MTA2, is
involved in the modulation of the enzymatic activity of
the HDAC1 complex (Zhang et al. 1999). CoREST and
Mta-lp proteins also form complexes with HDACs and
stimulate their enzymatic activities (Humphrey et al.
2001; You et al. 2001). The SANT domain of the nuclear
receptor/corepressors SMRT is a critical component of a
deacetylase activation domain (DAD) that binds and ac-
tivates HDAC3 as part of a histone interaction domain
(HID). HID enhances repression by increasing the affin-
ity of the DAD HDAC3 enzyme for its histone substrate.
The SANT-containing HID preferentially binds to un-
acetylated histone tails, implying that the SANT domain
participates in deciphering the histone code (Yu et al.
2003). Mutations in the SANT domain in the SWI/SNF-
complex protein SWI3p abolish the activity of the com-
plex in vivo (Boyer et al. 2002). Mutations that affect
only the DNA binding of SWI3, however, do not abrogate
its activity, suggesting that, in addition to DNA binding,
additional functions of the SANT domain are essential
(Boyer et al. 2002). In addition, the function of the chro-
matin remodeling RSC complex also depends on an in-
tact SANT domain. These results suggest that the SANT
domain is involved in the interaction with proteins rec-
ognizing various histone substrates and mediating suc-
cessional modifications.
A salient feature of the Myb DBD is that its three
SANT domains are tandemerized and that two of them,
R2 and R3, form a composite DNA-binding module that
is found in many Myb related proteins (Frampton et al.
1989; Tahirov et al. 2002). In this characteristic Myb-
repeat structure, the respective third  helices of both
SANT domains are positioned so as to form a kinked
extended helix that interacts with the cis-regulatory site
on DNA. Although the overall structure of SANT do-
mains appears to be conserved (Grune et al. 2003), it has
been suggested that SANT domain functions may vary
with respect to surface charge and that Myb-SANT do-
mains could be functionally divergent from other SANT
domains (Boyer et al. 2004). Yet, results presented here
show that the Myb–DBD couples histone substrate bind-
ing and catalysis with gene activation and that this es-
sential feature is lost in the oncogenic v-Myb variant.
The three amino acid substitutions in the DBD of v-
Myb act in concert to achieve a block in cell differentia-
tion and an acute myeloblastosis (Introna et al. 1990).
Although any back mutations affect both oncogenic
functions, the D117V back mutation still fails to bind
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C/EBP but regains H3 tail binding and exhibits an inter-
mediate myeloblast/promyelocyte phenotype (Introna et
al. 1990). This finding, together with data presented here,
suggests that the Myb–C/EBP interaction is largely re-
sponsible for cell differentiation, whereas abrogation of
H3 tail acetylation is crucial for the leukemogenic con-
version of the oncoprotein.
Materials and methods
Plasmid constructs
A PCR fragment corresponding to the DBD of the avian c-Myb
protein (amino acids 72–192) was generated and cloned in frame
with the LexA DBD in the pBTM 116 vector (Clontech). Lysine
amino acid 128 of the c-Myb DBD was mutated to methionine
by site directed mutagenesis (QuickChange, Stratagene). PCR-
generated fragments encoding human H3.3 amino acids 1–42
and 42–136, and human H3 amino acids 1–30 and 27–42 were
inserted into BamH1/EcoR1 sites in GST expression vector
pGEX4T-2 (Pharmacia). DNA fragments encoding human
c-Myb DBDs were generated by PCR and inserted into the
BamH1 site of pGEX4T-1 (Pharmacia) and into the BamH1 site
of the vector pCDA3.1A (Invitrogen) for mutagenesis. Amino
residues within the c-Myb DNA were mutated by site-directed
mutagenesis (QuickChange, Stratagene). C/EBP–Myb fusion
proteins were generated by cloning PCR-generated fragments
derived from C/EBP (CR1–4: amino acids 1–113) equipped
with optimized translation initiation sequences in frame to the
c-Myb or v-Myb PCR derivatives in pCDM8 (Invitrogen). The
AMV v-Myb back mutants were gifts from Thomas Graf (Albert
Einstein College of Medicine, New York, NY) (Introna et al.
1990). The PCR products from the v-Myb constructs were in-
serted into pCDNA3 vector carrying three C-terminal repeats of
Flag-tag sequences. The GST–H2A, GST–H2B, GST–H4, and
GST–H3 fusing protein expressing vectors were gifts from Dr.
A. Hecht (University of Freiburg, Freiburg, Germany) and were
described before (Hecht et al. 1995). The p300 expression vector
was gifts from Dr. R. Eckner (University of New Jersey, Newark,
NJ) (Eckner et al. 1994).
Yeast two-hybrid screening
The L40 yeast strain was sequentially transformed with the
pBTM116-Myb-K128M bait and a human bone marrow cDNA
library in the pGAD10 vector (Clontech). The screening proce-
dure was performed according to the manufacturer’s protocol
and as described (Ansieau and Leutz 2002).
In vitro transformation of bone marrow cells, tissue culture,
and immunoprecipitation
Bone marrow cells were prepared, infected with wild-type and
mutant c- and v-Myb chicken retroviruses as indicated. Trans-
formed colonies were isolated and expanded in the presence of
the cytokine cMGF in liquid culture as described (Kowenz-
Leutz et al. 1997). For ChIP analysis and endogenous gene acti-
vation assays, 2 × 107 cells were analyzed before or after over-
night treatment with 100 ng/mL TSA (Sigma). Hela and HEK
293 cells were grown in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% FBS. QT6 fibroblasts cells
were grown in DMEM supplemented with 2% chicken serum
and 8% FBS. Cells were transfected by calcium phosphate pre-
cipitation as described. Cell extracts were prepared in 10 mM
Tris-HCl (pH 7.9), 100 mM KCl, 2.5 mM MgCl2, 0.1% NP40, 10
µg/mL aprotinin, 2 µg/mL pepstatin, and 2 µg/mL leupeptin. For
IP, protein G-Sepharose was preincubated with the respective
antibodies and washed. Cell extracts were incubated with beads
overnight at 4°C (30–50 µL of beads per 50 µL of extract) in a
final volume of 1 mL buffer. Beads were washed, and bound
proteins were resolved by 10% SDS-PAGE and transferred to a
PVDF membrane (Millipore). Immunoblots were developed us-
ing the ECL-enhanced chemiluminescence kit (Amersham
Pharmacia Biotech).
ChIP assay
ChIP was performed essentially as described (Mo and Dynan
2002). Briefly, for each experiment, four plates (150 mm in di-
ameter) of cells were adjusted to 1% formaldehyde for 10 min,
quenched with glycine (final concentration, 0.125 M), har-
vested, and lysed, and chromatin was sheared by sonification.
Antibodies against acetylated histone H3 K18 and K23 were
purchased from Upstate. Following IP, cross-links were reversed
by heating for 5 h at 65°C. Nucleic acids were precipitated with
ethanol and resuspended in 600 µL of water, and PCR analysis
was performed (30 cycles: 1 min at 94°C, 2 min at 68°C; final
extension for 10 min at 68°C). One microliter to 9 µL of DNA
was incubated in the presence of 1 pmol of each primer, 1 mM
dNTPs, 2 µL of dimethyl sulfoxide, and 0.5 U of Taq DNA
polymerase in 10 mM Tris-Hcl (pH 8.3), 50 mM KCl, and 1.5
mM MgCl2. PCR products were analyzed on 2% agarose gels.
The following PCR primers were used: for the mim-1 gene (−292
to +37), 5-AAGCGTTAAGAAATGGTTCAACCAA-3 and 5-
ACCAGGCTGAGCAGGGCGATCAGG-3; for the lysozyme
gene promoter (−346 to +37), 5-GCCAAATTTGCATTGT
CAGGAAATG-3 and 5-GACCTCATGTTGCCAGTGTCGT




Single human recombinant histone proteins were purchased
from Upstate. GST–Myb DBD and GST histone fusion proteins
were expressed in bacteria and prepared according to standard
procedures. The Myb DBD was in vitro-translated and 35S-me-
thionine-labeled (TNT kit, Promega) in the presence of 100 µg/
mL each of aprotinin, pepstatin, and leupeptin. For GST–Myb
DBD and recombinant human histone protein interactions
studies, 2 µg of each histone proteine was incubated with 5 µg
of GST Myb DBD coupled to gluthathione-Sepharose (10 mM
Tris at pH 8.0, 150 mM NaCl, 1 mM MgCl, 0.5% Triton X-100,
10% glycerol, 1 mM dithiothreithol) for 3 h at 4°C. Beads were
repeatedly washed in binding buffer; bound proteins were sepa-
rated on 12% SDS-PAGE and detected by Coomassie staining.
For GST–histone and Myb–DBD interaction pull-downs, 15 µL
of in vitro translation cocktail was incubated with equal
amounts of bacterially expressed GST fusion proteins coupled
to glutathione-Sepharose overnight at 4°C. The beads were
washed six times with NETN (20 mM Tris at pH 8, 1 mM
EDTA, 50 mM NaCl, 0.5% NP40). Bound proteins were eluted
in SDS-PAGE sample buffer, separated on 10% SDS-PAGE, and
detected by fluorography.
Endogenous gene activation assay and Northern blot analysis
Total RNA was extracted using a guanidinium-isothiocyanate
method. Polyadenylated RNA was isolated, separated on 1.2%
formyldehyde-agarose gel, and blotted on nylon membranes; the
SANT domain function of Myb
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mRNA of differentiation specific genes was detected as de-
scribed (Kowenz-Leutz et al. 1997).
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